• No results found

Regulation of hypoxia-inducible factors by small ubiquitin-like modifiers

N/A
N/A
Protected

Academic year: 2021

Share "Regulation of hypoxia-inducible factors by small ubiquitin-like modifiers"

Copied!
13
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Regulation of hypoxia-inducible factors by small ubiquitin-like modifiers

Hagen, M. van

Citation

Hagen, M. van. (2010, May 26). Regulation of hypoxia-inducible factors by small ubiquitin- like modifiers. Retrieved from https://hdl.handle.net/1887/15552

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/15552

Note: To cite this publication please use the final published version (if applicable).

(2)

Regulation of Hypoxia-Inducible Factors by Small Ubiquitin-like Modifiers

Martijn van Hagen

(3)
(4)

Regulation of Hypoxia-Inducible Factors by Small Ubiquitin-like Modifiers

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van Rector Magnificus prof. mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op woensdag 26 mei 2010 klokke 13.45 uur

door

Martijn van Hagen

geboren te Delft

in 1979

(5)

Promotiecommissie

Promotor: Prof. Dr. H.J. Tanke Co-promotor: Dr. A.C.O. Vertegaal Overige leden: Prof. Dr. P. ten Dijke

Prof. Dr. L.H. Mullenders

Dr. M.A. Vooijs (UMC Utrecht en UMC Maastricht)

The studies described in this thesis were performed at the department of Molecular and Cellular Biology, Leiden University Medical Center.

This thesis was printed by Gildeprint Drukkerijen, Enschede.

(6)

Table of contents

Outline of the thesis 7

List of abbreviations used in the thesis 9

General introduction 15

Chapter 1: Introduction 1: Small Ubiquitin-like Modifiers M. van Hagen and A.C.O. Vertegaal.

Small Ubiquitin-like Modifiers and other Ubiquitin-like Proteins.

Vidal, CJ (ed.), Protein reviews series: Post-translational modifications in health and disease. (2010) Springer Business and media.

17

Chapter 2: Introduction 2: Hypoxia-Inducible Factors 47

Chapter 3: Inhibition of Hypoxia-Inducible Factor-1αααα by conjugation of Small Ubiquitin-like Modifiers

M. van Hagen, S.S. Abolvardi, J.V. Olsen, C.I. Balog, G. Roukens, D. Baker, P. Hensbergen and A.C.O. Vertegaal.

Submitted for publication.

61

Chapter 4: The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle J. Schimmel, K.M. Larsen, I. Matic, M. van Hagen, J. Cox, M. Mann,

J.S. Andersen and A.C.O. Vertegaal Mol. Cell Proteomics (2008), 7, 2107-2122.

89

Chapter 5: RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2αααα

M. van Hagen, R.M. Overmeer, S.S. Abolvardi and A.C.O. Vertegaal.

Nucleic Acids Res. (2010), 38, 1922-1931.

107

Chapter 6: In vivo identification of human Small Ubiquitin-like Modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy I. Matic, M. van Hagen, J. Schimmel, B. Macek, S.C. Ogg, M.H. Tatham, R.T. Hay, A.I. Lamond, M. Mann and A.C.O. Vertegaal

Mol. Cell Proteomics (2008), 7, 132-144.

123

Chapter 7: Summary and discussion 139

Chapter 8: Nederlandse samenvatting 149

Curriculum Vitae 155

List of publications 157

(7)
(8)

7

Outline of the thesis

The topic of this thesis is the molecular regulation of Hypoxia-Inducible Factors (HIFs) by sumoylation. Hypoxia-Inducible Factors are transcriptional regulators that mediate cell survival during reduced oxygen conditions (hypoxia). HIFs are extensively controlled by post-translational modifications. The aim of this thesis was to obtain novel insight in the post- translational modification of HIFs by sumoylation.

Chapters 1 and 2 are introductions on sumoylation and Hypoxia-Inducible Factors, respectively. A summary of current knowledge is provided based on published literature on both systems.

Chapter 3 describes the regulation of HIF-1α transcriptional activity by sumoylation via a novel SUMO acceptor site.

Chapter 4 describes crosstalk between sumoylation and ubiquitination, two similar but distinct post-translational modifications that act in concert to regulate the proteasomal degradation of a subset of protein targets.

Chapter 5 shows that sumoylation of HIF-2α marks it for proteasomal degradation during hypoxia, facilitated by E3 ubiquitin ligases RNF4 and VHL.

Chapter 6 presents data on the formation of SUMO chains made up of a mix of SUMO-1 and SUMO-2/3 and we show that HIF-1α is a target for SUMO chains in vitro.

Chapter 7 provides a summary and overall discussion of the thesis.

(9)

8

(10)

9

List of abbreviations used in the thesis

Aos1 Activation of Smt3p

ATG8 Autophagy-related protein 8 ATG12 Autophagy-related protein 12 bHLH basic helix-loop-helix

CBP cAMP response element binding (CREB)-binding protein CK2 Casein kinase 2

C-TAD C-terminal transactivation domain E1 SUMO activating enzyme

E2 SUMO protein carrier protein

E3 SUMO ligase

EPO Erythropoietin

EPAS Endothelial PAS domain protein ES Embryonic stem (cell)

FAT10 Ubiquitin-like protein FAT10 FIH Factor inhibiting HIF

FUBI Ubiquitin-like protein FUBI GMP1 GAP-modifying protein 1 HDAC Histone deacetylase

HECT Homologous to the E6-AP Carboxyl Terminus HIF Hypoxia-inducible factor

HSP90 Heat-shock protein 90

HUB1 Ubiquitin-like modifier HUB1 IκBα NFκB inhibitor α

iNOS Inducible nitric oxide synthase IR Internal repeats

ISG15 Interferon-stimulated gene 15 MAPK Mitogen-activated protein kinase Mdm2 Mouse double minute 2

MDR Multidrug resistance (gene)

NDSM Negatively charged amino acid-dependent sumoylation motif

NEDD8 Neural precursor cell expressed developmentally down-regulated protein 8

(11)

10 NFκB Nuclear factor κB

NO Nitric oxide NPC Nuclear pore complex

N-TAD N-terminal transactivation domain ODD Oxygen-dependent degradation (domain)

PAS Per-ARNT-SIM

Pc2 Polycomb protein 2

PCNA Proliferating cell nuclear antigen

PDSM Phosphorylation-dependent sumoylation motif PHD Proline hydroxylase

PIAS Protein inhibitor of activated STAT PIC1 PML-interacting clone 1

PML Promyelocytic leukemia protein PUP Prokaryotic ubiquitin-like protein RACK1 Receptor of activated protein C kinase 1 RanBP Ran-binding protein

RanGAP Ran GTPase-activating protein RING Really interesting new gene

RNF4 RING finger protein 4

RSUME RWD domain-containing sumoylation enhancer

RWD RING finger- and WD repeat-containing proteins and yeast DEAD-like helicases

SAE SUMO activating enzyme SENP SUMO protease

SILAC Stable-isotope labeling by amino acids in cell culture SIM SUMO interaction motif

Siz SAP and Miz-finger domain-containing protein 1 SMT3 Suppressor of mif two 3

STAT Signal transducer and activator of transcription SUMO Small ubiquitin-like modifier

TAF TBP-associated factor TBP TATA box binding protein TDG Thymine-DNA glycosylase

(12)

11 Uba2 Ubiquitin-activating enzyme E1-like Ubc9 Ubiquitin carrier protein 9

UBL1 Ubiquitin-like protein 1 UFM1 Ubiquitin-fold modifier 1 Ulp Ubiquitin-like-specific protease URM1 Ubiquitin-related modifier 1

VDU2 VHL-interacting deubiquitinating (enzyme) 2 VEGF Vascular endothelial growth factor

VHL Von Hippel Lindau

(13)

12

Referenties

GERELATEERDE DOCUMENTEN

In the last case, they often act as a switch where addition and removal of a functional group switches a protein ‘on’ or ‘off’ or regulates the binding to other proteins.

Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J and Sauer H (2003) Regulation of the multidrug resistance transporter P- glycoprotein

The file was divided into the following 5 main parts: patient identification (coded name, age, sex, whether proband or relative, and type[s] of coagulation defect), pedigree (number

Als de taak daarentegen meer van je vraagt dan je denkt aan te kunnen, dan vind je de taak (te) moeilijk: de taakzwaarte is (te) hoog. De ingeschatte taakzwaarte leidt vervolgens

The findings from the literature review will be discussed according to the National Department of Health (2009: 45) framework as it is a comprehensive approach that succeeds

Schematic representation of the field line density distribution in a conductivity detector cell with (a) axially and (b) radially mounted electrodes during the

frequency of eclampsia in the Standard treatment group (12%) and in the study groups, where effective antihypertensive treatment was given (5%), 240 patients would be required in

Prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffenng from stroke or venous thrombosis and among healthy subjects Blood